. 2019 Mar 1;316(5):H1005–H1013. doi: 10.1152/ajpheart.00091.2018

Table 1.

RV tissue hypertrophy and hemodynamic measurements in all experimental groups

	Control	PAH	Scaffold+MSCs	Scaffold Only	IV MSCs	IM MSCs
RV/BW	0.58 ± 0.03	1.58 ± 0.23^*	1.45 ± 0.18^*	1.28 ± 0.35^*	1.05 ± 0.28^*^†	0.92 ± 0.18^*^†
tPVR, mmHg·min⁻¹·ml	0.3 ± 0.1	0.8 ± 0.3^*	0.7 ± 0.2^*	0.6 ± 0.2	0.9 ± 0.2	1.0 ± 0.3^*
RV EDV, µl	352 ± 50	391 ± 118	474 ± 68	380 ± 84	407 ± 36	393 ± 36
RV ESV, µl	114 ± 80	199 ± 117	162 ± 83	128 ± 58	182 ± 69	191 ± 43
EF, %	73 ± 15	49 ± 16^*	63 ± 12	66 ± 14	55 ± 15	51 ± 7^*
HR, bpm	320 ± 40	335 ± 25	332 ± 39	337 ± 49	345 ± 31	336 ± 23
PAMP, mWatt/µl	0.67 ± 0.65	0.60 ± 0.35	1.46 ± 1.21^*^†	2.12 ± 3.01	0.38 ± 0.18	0.78 ± 0.57
dP/dt_min, mmHg/s	−1,325 ± 300	−3,580 ± 1,186^*	−3,033 ± 575^*	−2,440 ± 897^*	−3,147 ± 933^*	−2,853 ± 519^*
dP/dt_max, mmHg/s	2,544 ± 681	4,502 ± 580^*	4,854 ± 992^*	4,213 ± 2,400	4,642 ± 529^*	4,602 ± 1,140^*
PRSW	26 ± 10	68 ± 20^*	63 ± 21^*	67 ± 34	56 ± 17^*	58 ± 25^*
Ees, mmHg/μl	0.26 ± 0.09	0.44 ± 0.18^*	0.46 ± 0.13^*	0.47 ± 0.10	0.51 ± 0.23	0.32 ± 0.09
Ea, mmHg/μl	0.13 ± 0.03	0.24 ± 0.06^*	0.24 ± 0.07^*	0.23 ± 0.10	0.28 ± 0.11	0.34 ± 0.11^*
VVC, Ees/Ea	2.4 ± 1.3	1.7 ± 0.6	1.8 ± 0.6	2.7 ± 1.6	2.4 ± 1.9	1.0 ± 0.4
VVC, SV/ESV	3.7 ± 2.5	1.3 ± 1.0^*	2.1 ± 1.3	2.5 ± 1.6	1.5 ± 1.1^*	1.1 ± 0.3^*

Values are means ± SD; n = 8 for control, PAH and Scaffold+MSCs groups, and n = 5 for all other treatment groups. BW, body weight; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; HR, heart rate; PAMP, preload adjusted maximal power; PRSW, preload recruitable stroke work; RV, right ventricle; RV/BW, the ratio of RV tissue weight over body weight; SV, systolic volume; tPVR, total pulmonary vascular resistance; VVC, ventricular-vascular coupling.

P < 0.05 vs. control.

^†

P < 0.05 vs. PAH.